BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 8706243)

  • 1. Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein.
    Gudas JM; Nguyen H; Li T; Sadzewicz L; Robey R; Wosikowski K; Cowan KH
    Carcinogenesis; 1996 Jul; 17(7):1417-27. PubMed ID: 8706243
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationships between G1 arrest and stability of the p53 and p21Cip1/Waf1 proteins following gamma-irradiation of human lymphoma cells.
    Bae I; Fan S; Bhatia K; Kohn KW; Fornace AJ; O'Connor PM
    Cancer Res; 1995 Jun; 55(11):2387-93. PubMed ID: 7757991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1.
    Giannikaki E; Kouvidou C; Tzardi M; Stefanaki K; Koutsoubi K; Gregoriou M; Zois E; Kakolyris S; Mavroudi C; Delides G; Georgoulias V; Kanavaros P
    Anticancer Res; 1997; 17(3C):2123-7. PubMed ID: 9216675
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultraviolet radiation down-regulates expression of the cell-cycle inhibitor p21WAF1/CIP1 in human cancer cells independently of p53.
    Wang JA; Fan S; Yuan RQ; Ma YX; Meng Q; Goldberg ID; Rosen EM
    Int J Radiat Biol; 1999 Mar; 75(3):301-16. PubMed ID: 10203181
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Normal p53 status and function despite the development of drug resistance in human breast cancer cells.
    Wosikowski K; Regis JT; Robey RW; Alvarez M; Buters JT; Gudas JM; Bates SE
    Cell Growth Differ; 1995 Nov; 6(11):1395-403. PubMed ID: 8562478
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An abnormality in the p53 pathway following gamma-irradiation in many wild-type p53 human melanoma lines.
    Bae I; Smith ML; Sheikh MS; Zhan Q; Scudiero DA; Friend SH; O'Connor PM; Fornace AJ
    Cancer Res; 1996 Feb; 56(4):840-7. PubMed ID: 8631022
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Predictive value of p53, mdm-2, p21, and mib-1 for chemotherapy response in advanced breast cancer.
    Sjöström J; Blomqvist C; Heikkilä P; Boguslawski KV; Räisänen-Sokolowski A; Bengtsson NO; Mjaaland I; Malmström P; Ostenstadt B; Bergh J; Wist E; Valvere V; Saksela E
    Clin Cancer Res; 2000 Aug; 6(8):3103-10. PubMed ID: 10955790
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [WAF1/CIP1/p21 gene in wild type p53 and mutant p53 human breast cancer cell lines in relation to its cytobiological features].
    Jiang M; Shao Z; Wu J
    Zhonghua Zhong Liu Za Zhi; 1998 May; 20(3):181-4. PubMed ID: 10921001
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma.
    Suzuki A; Toi M; Yamamoto Y; Saji S; Muta M; Tominaga T
    Jpn J Cancer Res; 1998 Feb; 89(2):221-7. PubMed ID: 9548451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.
    Morgan SE; Kim R; Wang PC; Bhat UG; Kusumoto H; Lu T; Beck WT
    Oncogene; 2000 Oct; 19(43):5010-9. PubMed ID: 11042688
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Status of p53 phosphorylation and function in sensitive and resistant human cancer models exposed to platinum-based DNA damaging agents.
    Mujoo K; Watanabe M; Nakamura J; Khokhar AR; Siddik ZH
    J Cancer Res Clin Oncol; 2003 Dec; 129(12):709-18. PubMed ID: 14513366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems.
    Perego P; Giarola M; Righetti SC; Supino R; Caserini C; Delia D; Pierotti MA; Miyashita T; Reed JC; Zunino F
    Cancer Res; 1996 Feb; 56(3):556-62. PubMed ID: 8564971
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents.
    O'Connor PM; Jackman J; Bae I; Myers TG; Fan S; Mutoh M; Scudiero DA; Monks A; Sausville EA; Weinstein JN; Friend S; Fornace AJ; Kohn KW
    Cancer Res; 1997 Oct; 57(19):4285-300. PubMed ID: 9331090
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resistance of MCF7 human breast carcinoma cells to TNF-induced cell death is associated with loss of p53 function.
    Cai Z; Capoulade C; Moyret-Lalle C; Amor-Gueret M; Feunteun J; Larsen AK; Paillerets BB; Chouaib S
    Oncogene; 1997 Dec; 15(23):2817-26. PubMed ID: 9419972
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expression of p21waf1/Cip1, MDM2 and p53 in vivo: analysis of cytological preparations.
    Dowell SP; McGoogan E; Picksley SM; el-Deiry WS; Vogelstein B; Hall PA
    Cytopathology; 1996 Oct; 7(5):340-51. PubMed ID: 8911758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. p21(Waf1/Cip1) expression and the p53/MDM2 feedback loop in gastric carcinogenesis.
    Craanen ME; Blok P; Offerhaus GJ; Meijer GA; Dekker W; Kuipers EJ; Meuwissen SG
    J Pathol; 1999 Dec; 189(4):481-6. PubMed ID: 10629547
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders.
    Kanavaros P; Stefanaki K; Rontogianni D; Darivianaki K; Vlychou M; Papadaki E; Eliopoulos G; Bakiri M; Matsouka C; Kakolyris S; Georgoulias V
    Clin Exp Pathol; 1999; 47(5):231-8. PubMed ID: 10598372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diminished capacity for p53 in mediating a radiation-induced G1 arrest in established human tumor cell lines.
    Li CY; Nagasawa H; Dahlberg WK; Little JB
    Oncogene; 1995 Nov; 11(9):1885-92. PubMed ID: 7478618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
    Keshelava N; Zuo JJ; Chen P; Waidyaratne SN; Luna MC; Gomer CJ; Triche TJ; Reynolds CP
    Cancer Res; 2001 Aug; 61(16):6185-93. PubMed ID: 11507071
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in induction of p53, p21WAF1 and apoptosis in relation to cell cycle phase of MCF-7 cells treated with camptothecin.
    Deptala A; Li X; Bedner E; Cheng W; Traganos F; Darzynkiewicz Z
    Int J Oncol; 1999 Nov; 15(5):861-71. PubMed ID: 10536167
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.